
CLAIMS

1. A compound represented by the following structural formula:



Formula **I**

a tautomer thereof, a deuterated derivative of that compound or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

X1 is selected from S and -C**R2a** and **X2** is selected from S and -C**R2b**, wherein:

one of **X1** and **X2** is S;

when **X1** is S, then **X2** is -C**R2b**; and

when **X2** is S, then **X1** is -C**R2a**;

R1 is selected from hydrogen, halogen, cyano, -OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_3-C_6 cycloalkyl, and phenyl, wherein:

the C_1-C_6 alkyl of **R1** is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, $-NH_2$, -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, and C_1-C_4 alkoxy;

the C_1-C_6 alkoxy of **R1** is optionally substituted with 1 to 3 groups independently selected from halogen;

the C_3-C_6 cycloalkyl of **R1** is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, $-NH_2$, -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, C_1-C_4 alkyl, C_1-C_4 alkoxy, $-C(=O)NH_2$, -C(=O)NH(C_1-C_4 alkyl), and -C(=O)N(C_1-C_4 alkyl)$_2$; and

the phenyl of **R1** is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, $-NH_2$, -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, C_1-C_4 alkyl, C_1-C_4 alkoxy, $-C(=O)NH_2$, -C(=O)NH(C_1-C_4 alkyl), and -C(=O)N(C_1-C_4 alkyl)$_2$;

R2a is selected from hydrogen, halogen, cyano, -OH, =O, and C_1-C_6 alkyl, wherein:

the C_1-C_6 alkyl of $\mathbf{R^{2a}}$ is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, and C_1-C_4 alkoxy;

$\mathbf{R^{2b}}$ is selected from hydrogen, halogen, cyano, -OH, =O, and C_1-C_6 alkyl;

$\mathbf{R^{3a}}$ is selected from halogen, cyano, -OH, C_1-C_6 alkyl, and =O; wherein:


the C_1-C_6 alkyl of $\mathbf{R^{3a}}$ is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, and -OH;

$\mathbf{R^{3b}}$ is selected from C_1-C_2 alkyl and =O; wherein:

the C_1-C_2 alkyl of $\mathbf{R^{3b}}$ is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, and -OH;

------, for each occurrence, is a single bond when $\mathbf{R^{3a}}$ is selected from halogen, cyano, -OH, C_1-C_6 alkyl or when $\mathbf{R^{3b}}$ is selected from C_1-C_2 alkyl; or alternatively ======, for each occurrence, is a double bond when $\mathbf{R^{3a}}$ is =O or when $\mathbf{R^{3b}}$ is =O;

$\mathbf{R^4}$ is selected from C_1-C_6 alkyl, -C(=O)O(C_1-C_4 alkyl), C_2-C_6 alkynyl, and



, wherein:

the C_1-C_6 alkyl of $\mathbf{R^4}$ is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, -NH_2, -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, C_1-C_4 alkoxy, -C(=O)NH_2, -C(=O)NH(C_1-C_4 alkyl), -C(=O)N(C_1-C_4 alkyl)$_2$, C_3-C_6 cycloalkyl, 5 to 10-membered heterocyclyl, phenyl, and 5 to 10-membered heteroaryl;

Ring A is selected from C_3-C_{12} carbocyclyl, 3 to 12-membered heterocyclyl, C_6 and C_{10} aryl, and 5 to 10-membered heteroaryl, wherein **Ring A** is optionally substituted with 1, 2, 3, 4, or 5 $\mathbf{R^a}$ groups; wherein:

$\mathbf{R^a}$, for each occurrence, is independently selected from halogen, cyano, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_1-C_6 alkoxy, C_1-C_6 haloalkyl, C_1-C_6 haloalkenyl, C_1-C_6 haloalkoxy, -C(=O)N$\mathbf{R^h}\mathbf{R^i}$, -N$\mathbf{R^h}\mathbf{R^i}$, -N$\mathbf{R^h}$C(=O)$\mathbf{R^k}$, -N$\mathbf{R^h}$C(=O)O$\mathbf{R^k}$, -N$\mathbf{R^h}$C(=O)N$\mathbf{R^i}\mathbf{R^j}$, -N$\mathbf{R^h}$S(=O)$_p\mathbf{R^k}$, -O$\mathbf{R^k}$, -OC(=O)$\mathbf{R^k}$, -OC(=O)O$\mathbf{R^k}$, -OC(=O)N$\mathbf{R^h}\mathbf{R^i}$, -[O(CH_2)$_q$]$_r$O(C_1-C_6 alkyl), -S(=O)$_p\mathbf{R^k}$, -S(=O)$_p$N$\mathbf{R^h}\mathbf{R^i}$, -C(=O)O$\mathbf{R^k}$, C_3-C_{12} carbocyclyl, 3- to 12-membered heterocyclyl, C_6 and C_{10} aryl, and 5- to 10-membered heteroaryl; wherein:

the C_1-C_6 alkyl, C_1-C_6 alkoxy, and the C_2-C_6 alkenyl of $\mathbf{R^a}$ are each optionally substituted with 1 to 3 groups independently selected

from C_6 to C_{10} aryl (optionally substituted with 1 to 3 $\mathbf{R^m}$ groups), 5- to 10-membered heterocyclyl (optionally substituted with 1 to 3 $\mathbf{R^m}$ groups), 5- to 10-membered heteroaryl (optionally substituted with 1 to 3 $\mathbf{R^m}$ groups), cyano, -C(=O)$\mathbf{R^k}$, -C(=O)O$\mathbf{R^k}$, -C(=O)N$\mathbf{R^h}\mathbf{R^i}$, -N$\mathbf{R^h}\mathbf{R^i}$, -N$\mathbf{R^h}$C(=O)$\mathbf{R^k}$, -N$\mathbf{R^h}$C(=O)O$\mathbf{R^k}$, -N$\mathbf{R^h}$C(=O)N$\mathbf{R^i}\mathbf{R^j}$, -N$\mathbf{R^h}$S(=O)$_\mathbf{p}\mathbf{R^k}$, -O$\mathbf{R^k}$, -OC(=O)$\mathbf{R^k}$, -OC(=O)O$\mathbf{R^k}$, -OC(=O)N$\mathbf{R^h}\mathbf{R^i}$, -S(=O)$_\mathbf{p}\mathbf{R^k}$, -S(=O)$_\mathbf{p}$N$\mathbf{R^h}\mathbf{R^i}$, and C_3-C_6 carbocyclyl (optionally substituted with 1 to 3 $\mathbf{R^m}$ groups);

the C_3-C_{12} carbocyclyl, the 3 to 12-membered heterocyclyl, the C_6 and C_{10} aryl, and the 5 to 10-membered heteroaryl of $\mathbf{R^a}$ are each optionally substituted with 1 to 3 groups independently selected from halogen, cyano, C_1-C_4 alkyl, -N$\mathbf{R^h}\mathbf{R^i}$, and -O$\mathbf{R^k}$; wherein:

$\mathbf{R^h}$, $\mathbf{R^i}$, and $\mathbf{R^j}$, for each occurrence, are each independently selected from hydrogen, C_1-C_4 alkyl, C_6-C_{10} aryl, and C_3-C_6 cycloalkyl; wherein:

the C_1-C_4 alkyl of any one of $\mathbf{R^h}$, $\mathbf{R^i}$, and $\mathbf{R^j}$ is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, and -OH;

$\mathbf{R^k}$, for each occurrence, are each independently selected from hydrogen, C_1-C_4 alkyl, 5- to 10-membered heterocyclyl, and C_3-C_6 carbocyclyl; wherein:

the C_1-C_4 alkyl of any one of $\mathbf{R^k}$ is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, and -OH;

$\mathbf{R^m}$, for each occurrence, is independently selected from halogen, cyano, oxo, C_1-C_6 alkyl, C_1-C_6 alkoxy, -S(=O)$_\mathbf{p}\mathbf{R^k}$, and -O$\mathbf{R^k}$; wherein:

the C_1-C_6 alkyl of $\mathbf{R^m}$ is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, and -OH;

$\mathbf{R^5}$ is selected from C_1-C_6 alkyl, -C(=O)O(C_1-C_4 alkyl), C_3-C_{12} carbocyclyl, 3- to 12-membered heterocyclyl, C_6 and C_{10} aryl, and 5- to 10-membered heteroaryl; wherein:

the C_1-C_6 alkyl of $\mathbf{R^5}$ is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, -NH_2, -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, C_1-C_4

alkoxy,

-C(=O)NH_2, -C(=O)NH(C_1-C_4 alkyl), and -C(=O)N(C_1-C_4 alkyl)$_2$;

the C_3-C_{12} carbocyclyl, the 3 to 12-membered heterocyclyl, the C_6 and C_{10} aryl, and the 5 to 10-membered heteroaryl of **R^5** are each optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, -NH_2, -NH(C_1-C_4 alkyl) (optionally substituted with -OH), -N(C_1-C_4 alkyl)$_2$, C_1-C_5 alkyl (optionally substituted with -OH), C_1-C_4 alkoxy, -C(=O)NH_2, -C(=O)NH(C_1-C_4 alkyl), -NHC(=O)(C_1-C_4 alkyl), -C(=O)(C_1-C_4 alkoxy), and -C(=O)N(C_1-C_4 alkyl)$_2$;

k is an integer selected from 0, 1, and 2, wherein:

when **R^{3a}** is selected from halogen, cyano, -OH, and C_1-C_6 alkyl, k is 1 or 2; and

when **R^{3a}** is =O, k is 1;

m is an integer selected from 0, 1, and 2, wherein:


when **R^{3b}** is selected from C_1-C_2 alkyl, m is 1 or 2; and

when **R^{3b}** is =O, **m** is 1;


p is an integer selected from 1 and 2; and

q and **r** are each an integer selected from 1, 2, 3, and 4.

2. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1, wherein the compound is represented by one of the following structural formulae:



Formula **IIa**



Formula **IIb**


or is a tautomer thereof, a deuterated derivative of that compound or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

R^{2a} is selected from hydrogen, halogen, cyano, and C_1-C_4 alkyl; wherein:

the C_1-C_4 alkyl of $\mathbf{R^{2a}}$ is optionally substituted with 1 to 3 groups independently selected from halogen, -OH, and C_1-C_2 alkoxy;


$\mathbf{R^{2b}}$ is selected from hydrogen, halogen, cyano, and C_1-C_4 alkyl; and

k is an integer selected from 0, 1, and 2.

3. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 or claim 2, wherein $\mathbf{R^4}$ is selected from C_1-C_4 alkyl and 

; wherein:

the C_1-C_4 alkyl of $\mathbf{R^4}$ is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, $-NH_2$, $-NH(C_1$-C_4 alkyl), $-N(C_1$-C_4 alkyl$)_2$, C_1-C_2 alkoxy, C_3-C_6 cycloalkyl, 5 to 6-membered heterocyclyl, phenyl, and 5 to 6-membered heteroaryl.


4. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4, wherein $\mathbf{R^4}$ is selected from C_1-C_2 alkyl and 

; wherein:


the C_1-C_2 alkyl of $\mathbf{R^4}$ is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, and 5 to 6-membered heterocyclyl.

5. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4, wherein $\mathbf{R^4}$ is selected from $-CH_3$, $-CH_2OH$, and (tetrahydro-2H-pyran-4-yl)methyl.

6. The compound according to any one of claims 1 to 4, wherein the compound is represented by one of the following structural formulae:



Formula **IIIa**



Formula **IIIb**

or is a tautomer thereof, a deuterated derivative of that compound or tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein:


























Ring A, for each occurrence, is selected from C_3-C_6 cycloalkyl, 5- to 10-membered heterocyclyl, phenyl, and 5- to 10-membered heteroaryl; each of which is optionally substituted with 1, 2, 3, 4, or 5 $\mathbf{R^a}$ groups.


7. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4 and 6, wherein **Ring A** is selected from cyclopropyl, 5- to 10-membered heterocyclyl, phenyl, and 5- to 9-membered heteroaryl; each of which is optionally substituted with 1, 2, 3, 4, or 5 $\mathbf{R^a}$ groups.







8. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4, 6, and 7, wherein **Ring A** is selected from cyclopropyl, 5- to 10-membered heterocyclyl containing 1 to 3 heteroatoms selected from N and O, phenyl, and 5- to 9-membered heteroaryl containing 1 to 3 heteroatoms selected from N and O; each of which is optionally substituted with 1, 2, 3, 4, or 5 $\mathbf{R^a}$ groups.







9. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4 and 6 to 8, wherein **Ring A** is selected from cyclopropyl, 5-membered heterocyclyl containing 1 to 3 heteroatoms selected from N and O, 6-membered heterocyclyl containing 1 to 3 heteroatoms selected from N and O, 9-membered heterocyclyl containing 1 to 3 heteroatoms selected from N and O, 10-membered heterocyclyl containing 1 to 3 heteroatoms selected from N and O, phenyl, 5-membered heteroaryl containing 1 to 3







heteroatoms selected from N and O, 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N and O, and 9-membered heteroaryl containing 1 to 3 heteroatoms selected from N and O; each of which is optionally substituted with 1, 2, 3, 4, or 5 **R**[a] groups.







10. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4 and 6 to 9, wherein **Ring A** is selected from , , , , , , , , , , , , , , , , , , , , , , , , , and ; each of which is optionally substituted with 1, 2, 3, 4, or 5 **R**[a] groups.






11. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4 and 6 to 10, wherein **Ring A** is selected from 






, , , , , ,






, , , , , ,

, , , , , ,










, , , , , ,













, , , , ,

, , , , ,

, , , , ,

, , , ,










; each of which is optionally substituted with 1, 2, 3, 4, or 5 **R**[a] groups.

12. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4 and 6 to 11, wherein **R**[4] is selected from -CH_3 and **Ring A**; wherein **Ring A** is selected from 











, and
; each of which is optionally substituted with 1, 2, 3, 4, or 5 **R**[a] groups.

13. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 12, wherein **R**[5] is selected from C_1-C_4 alkyl, -C(=O)O(C_1-C_2 alkyl), C_3-C_6 cycloalkyl, and 5- to 10-membered heterocyclyl; wherein:

the C_1-C_4 alkyl of **R**[5] is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, and C_1-C_2 alkoxy; and

the C_3-C_6 cycloalkyl and the 5 to 10-membered heterocyclyl of $\mathbf{R^5}$ are each optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, C_1-C_2 alkyl, and C_1-C_2 alkoxy.


14. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 13, wherein $\mathbf{R^5}$ is selected from C_1-C_2 alkyl, C(=O)O(C_1-C_2 alkyl), cyclopropyl, cyclobutyl, and 5- to 6-membered heterocyclyl; wherein:

the C_1-C_2 alkyl of $\mathbf{R^5}$ is optionally substituted with 1 to 3 groups independently selected from F, Cl, Br, cyano, -OH, and C_1-C_2 alkoxy; and


the cyclopropyl, the cyclobutyl, and the 5- to 6-membered heterocyclyl of $\mathbf{R^5}$ are each optionally substituted with 1 to 3 groups independently selected from F, Cl, Br, cyano, -OH, C_1-C_2 alkyl, and C_1-C_2 alkoxy.

15. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 14, wherein $\mathbf{R^5}$ is selected from $-CH_3$, $-CH_2CH_3$, $-CH_2OH$, $-C(=O)OCH_3$, $-CH_2OCH_3$, $-CH(CH_3)_2$, cyclopropyl, difluorocyclopropyl, and tetrahydro-2H-pyranyl.

16. The compound according to any one of claims 1 to 15, wherein the compound is represented by one of the following structural formulae:



Formula **IVa**



Formula **IVb**

or is a tautomer thereof, a deuterated derivative of that compound or tautomer, or a pharmaceutically acceptable salt of any of the foregoing.

17. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 16, wherein $\mathbf{R^1}$ is selected from hydrogen, halogen, cyano, -OH, C_1-C_4 alkyl, C_1-C_4 alkoxy, and C_3-C_6 cycloalkyl; wherein:

the C_1-C_4 alkyl of $\mathbf{R^1}$ is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, and C_1-C_2 alkoxy;

the C_1-C_4 alkoxy of $\mathbf{R^1}$ is optionally substituted with 1 to 3 independently selected halogen groups; and

the C_3-C_6 cycloalkyl of $\mathbf{R^1}$ is optionally substituted with 1 to 3 groups independently selected from halogen, cyano, -OH, and C_1-C_2 alkoxy.

18. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 17, wherein $\mathbf{R^1}$ is selected from F, Cl, Br, C_1-C_4 alkyl, and C_3-C_6 cycloalkyl; wherein:

the C_1-C_4 alkyl of $\mathbf{R^1}$ is optionally substituted with 1 to 3 groups independently selected from halogen and -OH; and

the C_3-C_6 cycloalkyl of $\mathbf{R^1}$ is optionally substituted with 1 to 3 groups independently selected from halogen, and -OH.

19. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 18, wherein $\mathbf{R^1}$ is selected from F, Cl, Br, C_1-C_4 alkyl, and C_3-C_6 cycloalkyl; wherein:

the C_1-C_4 alkyl of $\mathbf{R^1}$ is optionally substituted with 1 to 3 groups independently selected from halogen and -OH; and

the C_3-C_6 cycloalkyl of $\mathbf{R^1}$ is optionally substituted with 1 to 3 groups independently selected from halogen, and -OH.

20. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 16, wherein $\mathbf{R^1}$ is selected from Cl, Br, $-CH_3$, $-CF_3$, $-CH_2CH_3$, $-CH(CH_3)_2$, $-CH_2CHF_2$, $-CH_2CH(CH_3)_2$, difluorocyclobutyl, and cyclohexyl.

21. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 20, wherein $\mathbf{R^1}$ is Cl.

22. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 21, wherein $\mathbf{R^{3a}}$ is selected from halogen, -OH, and C_1-C_4 alkyl; wherein:


the C_1-C_4 alkyl of $\mathbf{R^{3a}}$ is optionally substituted with 1 to 3 groups independently selected from halogen and -OH.

23. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 22, wherein $\mathbf{R^{3a}}$ is selected from F, Cl, Br, -OH, and C_1-C_2 alkyl; wherein:


the C_1-C_2 alkyl of $\mathbf{R^{3a}}$ is optionally substituted with 1 to 3 groups independently selected from F, Cl, and -OH.

24. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 23, wherein $\mathbf{R^{3a}}$ is selected from F, -OH, $-CH_3$, $-CHF_2$, and CH_2OH.

25. The compound according to any one of claims 1 to 4 and 6 to 24, wherein the compound is represented by one of the following structural formulae:



Formula **Va**



Formula **Vb**

or is a tautomer thereof, a deuterated derivative of that compound or tautomer, or a pharmaceutically acceptable salt of any of the foregoing.

26. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4 and 6 to 25, wherein $\mathbf{R^a}$, for each occurrence, is independently selected from halogen, cyano, C_1-C_6 alkyl, C_1-C_4 alkoxy, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, $-C(=O)N\mathbf{R^h}\mathbf{R^i}$, $-N\mathbf{R^h}\mathbf{R^i}$, $-N\mathbf{R^h}C(=O)\mathbf{R^k}$, $-O\mathbf{R^k}$, $-[O(CH_2)_\mathbf{q}]_rO(C_1$-$C_6$ alkyl),

-S(=O)$_2$**R^k**, -S(=O)$_2$N**R^{h}R^i**, C_3-C_6 cycloalkyl, 5- to 10-membered heterocyclyl, phenyl, and 5- to 8-membered heteroaryl; wherein:

the C_1-C_6 alkyl of **R^a** is optionally substituted with 1 to 3 groups independently selected from cyano, -C(=O)N**R^{h}R^i**, -N**R^{h}R^i**, -N**R^h**C(=O)**R^k**, -N**R^h**C(=O)O**R^k**, -N**R^h**C(=O)N**R^{i}R^j**, -N**R^h**S(=O)$_p$**R^k**, -O**R^k**, -S(=O)$_2$**R^k**, -S(=O)$_p$N**R^{h}R^i**, and C_3-C_6 cycloalkyl;

the C_3-C_6 cycloalkyl, the 5 to 10-membered heterocyclyl, the phenyl, and the 5- to 8-membered heteroaryl of **R^a** are each optionally substituted with 1 to 3 groups independently selected from halogen, C_1-C_2 alkyl, and -O**R^k**; wherein:

R^h, **R^i**, and **R^j**, for each occurrence, are each independently selected from hydrogen, C_1-C_2 alkyl, cyclopropyl, and cyclobutyl; wherein:

the C_1-C_2 alkyl of any one of **R^h**, **R^i**, and **R^j** is optionally substituted with 1 to 3 groups independently selected from halogen and -OH;

R^k, for each occurrence, are each independently selected from hydrogen and C_1-C_4 alkyl; wherein:

the C_1-C_4 alkyl of **R^k** is optionally substituted with 1 to 3 groups independently selected from halogen and -OH; and

q and **r** are each an integer selected from 1, 2, and 3.

27. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4 and 6 to 26, wherein **R^a**, for each occurrence, is independently selected from halogen, cyano, C_1-C_6 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, -C(=O)N**R^{h}R^i**, -N**R^{h}R^i**, -N**R^h**C(=O)**R^k**, -O**R^k**, -[O(CH$_2$)$_q$]$_r$O(C_1-C_4 alkyl), -S(=O)$_2$**R^k**, -S(=O)$_2$N**R^{h}R^i**, cyclopropyl, cyclobutyl, 5 to 6-membered heterocyclyl, phenyl, and 5 to 6-membered heteroaryl; wherein:

the C_1-C_6 alkyl of **R^a** is optionally substituted with 1 to 3 groups independently selected from cyano, -C(=O)N**R^{h}R^i**, -N**R^{h}R^i**, -O**R^k**, cyclopropyl, and cyclobutyl;

the cyclopropyl, the cyclobutyl, the 5 to 6-membered heterocyclyl, the phenyl, and the 5 to 6-membered heteroaryl of **R^a** are each optionally substituted with 1 to 3 groups independently selected from halogen, -CH_3, -OH, and -OCH_3; wherein:

R^h and **R^i**, for each occurrence, are each independently selected from hydrogen, -CH_3, cyclopropyl, and cyclobutyl; wherein:

the -CH_3 of any one of **R^h** and **R^i** is optionally substituted with 1 to 3 groups independently selected from F, Cl, and -OH;

$\mathbf{R^k}$, for each occurrence, is each independently selected from hydrogen and -CH_3; wherein:

the -CH_3 of $\mathbf{R^k}$ is optionally substituted with 1 to 3 groups independently selected from halogen and -OH.

28. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4 and 6 to 27, wherein $\mathbf{R^a}$, for each occurrence, is independently selected from F, Cl, Br, cyano, C_1-C_6 alkyl, C_1-C_2 alkoxy, C_1-C_2 haloalkyl, -C(=O)N$\mathbf{R^h R^i}$, -N$\mathbf{R^h R^i}$, -N$\mathbf{R^h}$C(=O)$\mathbf{R^k}$, -O$\mathbf{R^k}$, -[O(CH_2)$_\mathbf{q}$]$_\mathbf{r}$O(C_1-C_2 alkyl), -S(=O)$_2\mathbf{R^k}$, -S(=O)$_2$N$\mathbf{R^h R^i}$, cyclopropyl, cyclobutyl, 5-membered heterocyclyl, phenyl, and 6-membered heteroaryl; wherein:

the C_1-C_6 alkyl of $\mathbf{R^a}$ is optionally substituted with 1 to 3 groups independently selected from cyano, -C(=O)N$\mathbf{R^h R^i}$, -O$\mathbf{R^k}$, and cyclopropyl;

the cyclopropyl, the cyclobutyl, the 5 to 6-membered heterocyclyl, the phenyl, and the 5 to 6-membered heteroaryl of $\mathbf{R^a}$ are each optionally substituted with 1 to 3 groups independently selected from halogen, -CH_3, -OH, and -OCH_3; wherein:

$\mathbf{R^h}$ and $\mathbf{R^i}$, for each occurrence, are each independently selected from hydrogen, -CH_3, and cyclopropyl; wherein:


the -CH_3 of any one of $\mathbf{R^h}$ and $\mathbf{R^i}$ is optionally substituted with 1 to 3 groups independently selected from F, Cl, and -OH;

$\mathbf{R^k}$, for each occurrence, is each independently selected from hydrogen and -CH_3; and


q and **r** are each an integer selected from 1 and 2.

29. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claims 1 to 4 and 6 to 28, wherein $\mathbf{R^a}$, for each occurrence, is independently selected from F, cyano, -OH, -CH_3, -CF_3, -$CH(CH_3)_2$, -$(CH_2)_2$OH , -$(CH_2)_2OCH_3$, -$CH_2CH(OH)C_2H_5$, -$CH_2C(CH_3)(CH_2OH)_2$, -OCH_3, -OCH_2CH_3, -$[O(CH_2)_2]_2OCH_3$, -$CH_2C(=O)NHCH_3$, -$(CH_2)_2SO_2CH_3$, -$CH_2C(=O)N(CH_3)_2$, -CH_2(cyclopropyl), -$C(=O)NH_2$, -C(=O)NH(cyclopropyl), -NH_2, -$NHCH_3$, -$N(CH_3)_2$, -$NHC(CH_3)_2CH_2OH$, -$NHC(=O)CH_3$, -SO_2CH_3, -SO_2NH_2, cyclopropyl, 2-methoxyphenyl, N-methylpiperazinyl, tetrahydro-2H-pyranyl, methylpyrazolyl, pyridinyl, and tetrahydrothiophenyl 1,1-dioxide.


30. The compound according to claim 1, wherein the compound is represented by one of the following structural formulae:




Formula **I'**




Formula **IIa'**




Formula **IIb'**




Formula **IIIa'**




Formula **IIIb'**




Formula **IVa'**



Formula **IVb'**




Formula **Va'**





Formula **Vb'**


or is a tautomer thereof, a deuterated derivative of that compound or tautomer, or a pharmaceutically acceptable salt of any of the foregoing.


31. A compound selected from:



1



2



3



4



5



6



7



8



9



10



11



12



13



14


15



16


17



18




19




20




21




22




23




24




25




26




27




28




29




30




31




32




33




34




35




36




37




38




39




40




41




42




43




44




45




46




47




48




49




50




51




52




53




54




55




56




57




58




59




60




61




62




63




64




65




66




67




68




69




70




71




72




73




74




75




76




77




78




79




80




81




82




83




84




85




86




87




88




89




90




91




92




93




94




95




96




97




98




99




100




101




102




103




104




105




106





107





108



109



110



111



112



113



114



115



116



117



118



119



120



121



122


123



124


125



126




127




128




129




130




131




132




133




134




135




136




137




138




139




140




141




142




143




144




145




146




147




148




149




150




151




152




153




154




155




156




157




158




159




160




161




162




163




164




165




166




167




168




169




170




171




172




173




174




175




176




177




178




179




180




181




182




183




184




185




186




187




188




189




190




191




192




193




194




195




196




197




198




199




200




201




202




203




204




205




206




207




208




209




210




211




212




213




214




215




216




217




218




219




220




221




222




223




224




225




226




227




228




229




230




231




232




233




234




235




236




237




238




239




240




241




242




243




244




245




246




247




248




249




250





251





252



253



254



255



256



257



258



259



260



261



262



263



264


265



266


267



268




269




270




271




272




273




274




275




276




277




278




279




280




281




282




283




284




285




286




287




288




289




290




291




292




293




294




295




296




297




298





299





300



301



302



303



304



305



306



307



308



309



310



311



312



313



314



315



316



317



318



319



320



321



322



323



324



325



326



327



328


329



330


331



332




333




334




335




336




337




338




339




340




341




342




343




344




345




346





347





348



349



350



351



352



353



354



355



356



357



358



359



360


361



362


363



364




365




366




367




368




369




370




371




372




373




374




375




376




377




378



379



380



tautomers thereof, deuterated derivatives of those compounds and tautomers, and pharmaceutically acceptable salts of any of the foregoing.

32. A pharmaceutical composition comprising at least one entity according to any one of claims 1 to 31 and a pharmaceutically acceptable carrier.

33. Use of ~~A method of treating focal segmental glomerulosclerosis and/or non-diabetic kidney disease comprising administering to a patient in need thereof~~ at least one entity according to any one of claims 1 to 31 or a pharmaceutical composition according to claim 32, in the manufacture of a medicament for treating focal segmental glomerulosclerosis and/or non-diabetic kidney disease.

34. Use of ~~A method of inhibiting APOL1 activity comprising contacting said APOL1 with~~ at least one entity according to any one of claims 1 to 31 or a pharmaceutical composition according to claim 32, in the manufacture of a medicament for inhibiting APOL1 activity.

~~35. A silicon derivative of the at least one entity according to any one of claims 1 to 31.~~

~~36. A pharmaceutical composition comprising a silicon derivative according to claim 35.~~

~~37. A method of treating focal segmental glomerulosclerosis and/or non-diabetic kidney disease comprising administering to a patient in need thereof a silicon derivative according to claim 35 or a pharmaceutical composition according to claim 36.~~

~~38. A boron derivative of the at least one entity according to any one of claims 1 to 31.~~

~~39. A pharmaceutical composition comprising a boron derivative according to claim 38.~~

~~40. A method of treating focal segmental glomerulosclerosis and/or non-diabetic kidney disease comprising administering to a patient in need thereof a boron derivative according to claim 38 or a pharmaceutical composition according to claim 39.~~

~~41. A phosphorus derivative of at least one entity according to any one of claims 1 to 31.~~

~~42. A pharmaceutical composition comprising a phosphorus derivative according to claim 41.~~

~~43. A method of treating focal segmental glomerulosclerosis and/or non-diabetic kidney disease comprising administering to a patient in need thereof a phosphorus derivative according to claim 41 or a pharmaceutical composition according to claim 42.~~

~~44~~35. Use of ~~A method of treating an APOL1-mediated disease comprising administering to a patient in need thereof~~ at least one entity according to any one of claims 1 to 31 or a pharmaceutical composition according to claim 32, in the manufacture of a medicament for treating an APOL1-mediated disease.

~~45~~36. The ~~method~~ use according to claim ~~44~~35, wherein the APOL1-mediated disease is cancer.

~~46~~37. The ~~method~~ use according to claim ~~44~~ 35 or claim ~~45~~36, wherein the APOL1-mediated disease is pancreatic cancer.

~~47~~38. The ~~method~~ use according to claim ~~44~~35, wherein the APOL1-mediated disease is an APOL1-mediated kidney disease.

39. At least one entity according to any one of claims 1 to 31 or a pharmaceutical composition according to claim 32, for use in the treatment of focal segmental glomerulosclerosis and/or non-diabetic kidney disease.

40. At least one entity according to any one of claims 1 to 31 or a pharmaceutical composition according to claim 32, for use in inhibiting APOL1 activity.

41. At least one entity according to any one of claims 1 to 31 or a pharmaceutical composition according to claim 32, for use in the treatment of an APOL1-mediated disease.